Trial · NCT04668209
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | Through Day 60 | Intent to treat population (all participants assigned to Silmitasertib/Combo, or Standard of Care). The median treatment duration of Silmitasertib was 14 days. The treatment Durations (days) = the last administration date - the first administration. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Through Day 28 | Days | MEAN | |
| SECONDARY | To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Through hospital discharge, an average of 28 days | Days | MEAN | |
| SECONDARY | To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Through Day 28 | Days | MEAN | |
| SECONDARY | To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Assessed on Day 14 and Day 28 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Through Day 28 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Preliminary Evidence of Anti-viral Activity of CX-4945 as Compared to the Control Arm. | Assessed at Day 1, Day 8, Day 14 and Day 28 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Preliminary Evidence of Anti-viral Activity of CX-4945 as Compared to the Control Arm. | Through Day 14 | No data collected for this outcome analysis. | ||
| SECONDARY | Number of Days Hospitalized | Through Day 28 | Days | MEAN | |
| SECONDARY | To Evaluate Changes in IL-6 Level | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Changes in CRP | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Changes in LDH | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Changes in CPK | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Changes in Ferritin | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | To Evaluate Changes in D-dimer | Assessed on Days 1, 4, 8, 11, and 14 | Missing data explains the discrepancy in the total analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Days of Supplemental Oxygen Use | Through Day 28 | Days | MEAN | |
| SECONDARY | All-cause Mortality Status | Through Day 60 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Days of On-invasive Ventilation/High Flow Oxygen | Through Day 28 | Days | MEAN | |
| SECONDARY | Number of Days of Invasive Mechanical Ventilation/ECMO | Through Day 28 | Days | MEAN | |
| SECONDARY | Number of Patients Returned to Room Air | Through Day 28 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04668209/outcomes